2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Non-Biological Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bleeding and Clotting, Platelet Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3858 STAG2 multi‑hit evolution defines a high-risk subset of myelodysplastic syndrome and reveals convergent evolutionary targeting of cohesin

Eno-obong Blessing Udoh, BS, Yi Chen, MD, PhD2, Matteo D'Addona, MD3, Edna Marie Stewart, B.S., M.S.4, Rongjia Deng, MD5, Felipe de Almeida Sartori6, Serhan Unlu, MD7, Zachary Brady, BS8, Ruowei Zhu9, Xiaoyi Cheng, PhD10, Viviana Scoca, PhD11, Jane J. Xu, PhD12, Sergei Doulatov, PhD13, Karl Theil, MD14, David Bosler, MD15, Valeria Visconte, PhD16, Jaroslaw P. Maciejewski, MD, PhD, FACP17, Aaron Viny, MD, MS18
1 Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States
2 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
3 Scuola Medica Salernitana, University of Salerno, Salerno, Italy
4 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
5 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
6 Case Western Reserve University, Cleveland, Ohio, United States, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
7 Taussig Cancer Institute, Cleveland, Ohio, United States
8 Taussig Cancer Institute, Cleveland, Ohio, United States
9 Columbia University Irving Medical Center, New York, New York, United States
10 Columbia University Irving Medical Center, New York, New York, United States
11 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
12 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
13 Columbia University Irving Medical Center, New York, New York, United States
14 Cleveland Clinic Foundation, Cleveland, Ohio, United States
15 Cleveland Clinic Foundation, Cleveland, Ohio, United States
16 Taussig Cancer Institute, Cleveland, Ohio, United States
17 Taussig Cancer Institute, Cleveland, Ohio, United States
18 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States

Background: Disease evolution in myelodysplastic syndrome (MDS) is driven by the acquisition of somatic mutations that establish clonal dominance and define clinical phenotypes. Mutations in the cohesin complex are enriched in high-risk MDS and secondary acute myeloid leukemia (s-AML). Among these, STAG2 is the most frequently mutated and predominantly results in loss-of-function mutations.  Located on the X chromosome, STAG2 is considered a monoallelic tumor suppressor in hematopoietic cells, as a single inactivating mutation is sufficient to disrupt cohesin function in the hemizygous state. Yet, the significance of multiple mutations within this X-linked gene remains unknown.

Methods: We analyzed a cohort of 1,967 adult patients with myeloid neoplasms and identified 233 cases (12%) harboring STAG2 mutations, including 38 (16%) with multiple STAG2 hits and 195 (84%) with single hits. Detailed assessments of clinical, genomic, and clonal hierarchy were performed for all cases. Data on relevant clinical parameters and next-generation sequencing performed at the time of diagnosis were obtained from electronic medical records. For patients with >1 STAG2 mutation, we approximated clonal hierarchy using a variant allele frequency (VAF)-based method. The 1st STAG2 hit was classified relative to other co-mutations as ancestral/dominant/DOM (STAG2 VAF ≥ 5% above the next highest), ancestral/co-dominant/COD (within 5% of the next highest VAF, including ties), or secondary/subclonal/SEC (≥1 mutation ≥5% above STAG2 VAF). To further investigate the molecular basis of recurrent STAG2 acquisition, we performed long-read nanopore sequencing in representative cases with STAG2 mutations within phaseable proximity (~5 kb apart).

Results: Within the multi-hit STAG2 cohort, 31/38 cases had 2-hits, 5/38 had 3-hits, and 2/38 had 4-hits. All patients in this cohort had at least one truncating mutation (nonsense, splice-site, or frameshift), and only 3 cases had a combination of both missense and truncating mutations.  In contrast, the single-hit cohort was represented by 77% truncating mutations and 19% missense mutations. There was no difference in the distribution and age at diagnosis of MDS vs. AML between the two groups, and the male: female (M: F) ratio was 3.4 in MDS patients with multi-hit and 4.5 in AML. Overall, patients with multi-hit STAG2 mutations exhibited increased multilineage dysplasia compared with single-hit cases, specifically in the myeloid and megakaryocytic lineages (p = 0.02), Within the MDS cohort, patients with multiple STAG2 hits were more likely to have the MDS-EB2 subtype compared to those with single hits (45.5% vs. 16.75%; p = 0.0046), which correlated with a greater blast percentage in this group (4% vs. 8%; p = 0.04). Clonal hierarchy assessment showed that 40% of 1st hit mutations in the multiple hit cohort were ancestral (DOM/COD) vs. 60% which were secondary to other co-mutations. Examination of the co-mutational patterns revealed that ancestral mutations were more likely to be followed by a second STAG2 hit while secondary mutations were likely to be preceded by mutations in ASXL1, TET2, and BCOR.

Long-read nanopore sequencing demonstrated that independent truncating STAG2 mutations resided on distinct DNA molecules rather than occurring sequentially within the same allele, providing direct evidence for convergent evolutionary targeting of STAG2. Cohort-level VAF patterns were consistent with recurrent evolutionary targeting of STAG2 across related clonal populations. Lastly, multi-hit STAG2 patients experienced inferior overall survival compared to those with single hits, an effect driven primarily by patients with MDS (25months vs. 16.7 months, p = 0.002), and this survival difference was independent of clonal hierarchy.

Conclusions: Here, we define a distinct subgroup of STAG2-mutant myeloid neoplasms characterized by multiple mutations within the same gene and associated with adverse clinical outcomes in MDS. The observation of increased multilineage dysplasia in this cohort supports a model in which cumulative disruption of cohesin function may drive disease severity. Our clonal analysis and VAF assessment also demonstrate that despite the canonical view of STAG2 as a single-hit X-linked tumor suppressor, additional STAG2 mutations are repeatedly selected during clonal evolution via convergence and suggest parallel, progressive disruption of cohesin function that contributes to disease aggressiveness.
Eno-obong Blessing Udoh, BS: No relevant conflicts of interest to declare.